<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761276</url>
  </required_header>
  <id_info>
    <org_study_id>LUCIDIS2021</org_study_id>
    <nct_id>NCT04761276</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Long-term Safety for Lucidis Instant Focus© - PMCF Study Protocol</brief_title>
  <official_title>Evaluation of Efficacy and Long-term Safety for Lucidis Instant Focus© - PMCF Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SAV-IOL SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEISO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SAV-IOL SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study is to evaluate efficacy and long-term safety of the Lucidis lens.&#xD;
      Through this study, the objective is to obtain an up-to-date clinical evaluation of the&#xD;
      medical device thus supplementing data from experimental trials. Clinical and functional&#xD;
      changes in the implanted eyes among a patient population in which the opaque crystalline lens&#xD;
      resulting from cataract was removed and replaced by a Lucidis IOL will be described.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refractory function in patients with a cataract is mainly restored by implanting intra-ocular&#xD;
      lenses (IOL) destined to replace the crystalline lens. While new surgical techniques for&#xD;
      removing the crystalline lens have been developed, these lenses have been considerably&#xD;
      perfected to resemble the natural crystalline lens as closely as possible.&#xD;
&#xD;
      The objectives of the study is to evaluate efficacy and long-term safety of the Lucidis lens.&#xD;
      Through this study, the objective is to obtain an up-to-date clinical evaluation of the&#xD;
      medical device thus supplementing data from experimental trials. Clinical and functional&#xD;
      changes in the implanted eyes among a patient population in which the opaque crystalline lens&#xD;
      resulting from cataract was removed and replaced by a Lucidis IOL will be described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity measure BCVA photopic</measure>
    <time_frame>1 year</time_frame>
    <description>Far Best Corrected Visual Acuity in photopic conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity measure UCVA photopic</measure>
    <time_frame>1 year</time_frame>
    <description>Near, intermediate and far Uncorrected visual acuity in photopic conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity measure BCVA mesopic</measure>
    <time_frame>1 year</time_frame>
    <description>Far Best Corrected Visual Acuity in mesopic conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity measure UCVA mesopic</measure>
    <time_frame>1 year</time_frame>
    <description>Near, intermediate and far Uncorrected visual acuity in mesopic conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity measure photopic</measure>
    <time_frame>1 year</time_frame>
    <description>Contrast sensitivity in photopic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity measure mesopic</measure>
    <time_frame>1 year</time_frame>
    <description>Contrast sensitivity in mesopic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse reactions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Lucidis Intra-ocular lens (IOL)</arm_group_label>
    <description>Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical implantation of intra ocular lens</intervention_name>
    <description>Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.</description>
    <arm_group_label>Lucidis Intra-ocular lens (IOL)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with significant reduction in visual acuity and/or visual comfort from&#xD;
        cataract requiring intra ocular lens implantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients (≥18 years)&#xD;
&#xD;
          -  having agreed to take part in the study and complete post-operative follow-up&#xD;
             requirements (by having signed the information leaflet-informed consent form);&#xD;
&#xD;
          -  with;&#xD;
&#xD;
          -  for whom the physician made the decision to implant a Lucidis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient included in an interventional therapeutic trial at the time of inclusion;&#xD;
&#xD;
          -  patient presenting contraindications for the implantation of an intraocular lens;&#xD;
&#xD;
          -  patient presenting an ophthalmic disorder liable to interfere with the study&#xD;
             endpoints;&#xD;
&#xD;
          -  patient presenting with an astigmatism ≥1.0 D;&#xD;
&#xD;
          -  patient refusing or unable to comply with the follow-up procedures in the study&#xD;
             (patient unable to be reached by telephone, liable to be lost to follow-up, etc.);&#xD;
&#xD;
          -  History of previous intraocular surgery in the study eye in the previous 6 months;&#xD;
&#xD;
          -  patient is pregnant, breast-feeding or unable to make the decision to participate in a&#xD;
             clinical investigation (e.g. mentally ill or handicapped person)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Hashemi, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut jules gonin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Hashemi, Pr</last_name>
    <phone>+41 21 626 81 11</phone>
    <email>kattayoon.hashemi@fa2.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Jules Gonin</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Hashemi, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://sav-iol.com/</url>
    <description>SAV IOL website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT04761276/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT04761276/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

